Hello, and welcome to the Novan, Inc. Quarterly Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode. If anyone requires operator assistance during the event, please press star then zero on your telephone keypad. Following the presentation, there will be a question and answer session. Note that this webcast is being recorded at the company's request, and a replay will be made available on the company's website following the end of the event. At this time, I'd like to remind our listeners that remarks made during this webcast may state management's intentions, beliefs, expectations, or future projections. These are forward-looking statements and involve risk and uncertainties. Forward-looking statements on this call are made pursuant to the safe harbor provisions of the federal securities laws and are based on Novan's current expectations and actual results could differ materially. As a result, you should not place undue reliance on any forward-looking statements. Some of the factors that could cause actual results to differ materially from these contemplated by such forward-looking statements are discussed in the periodic reports Novan files with the Securities and Exchange Commission. These documents are available in the investors section of the company's website and on the Securities and Exchange Commission's website. We encourage you to review these documents carefully. Additionally, certain information contained in this webcast relates to or is based on studies, publications, surveys, and other data obtained from third-party sources and the company's own estimates and research. While the company believes these third-party sources to be reliable, it has not independently verified such information. Joining us on today's call from the Novan leadership team are Paula Brown Stafford, Chairman, President, and Chief Executive Officer, John A. Donofrio, Chief Operating Officer of Novan and President of EPI Health, and John M. Gay, Chief Financial Officer. I would now like to turn the call over to Paula Brown Stafford, Chairman, President, and Chief Executive Officer. Please proceed. Thank you, Howard. Good morning, everyone, and thank you for joining our corporate update, including Novan's financial results for the first quarter of 2022. On March 11, we announced exciting news for Novan. We had closed on the acquisition of EPI Health, and therefore, we emerged as a fully integrated medical dermatology company. This is truly a foundational leap forward for Novan. We now have marketed products and a proprietary R&D platform technology to fuel future organic growth for Novan. A great example of the value we have added is Rhofade, a topical cream prescribed to treat ongoing facial redness associated with rosacea in adults. EPI Health acquired Rhofade in 2019 and relaunched just in time for the pandemic to hit. As dermatologists' offices began to reopen in late 2021 and early 2022, we've seen a nice increase in scripts written for Rhofade. The quotes here are from two patients who are seeing their medical needs met, something that we're striving to do at Novan. It's the tangible value of Novan's products for the patients we serve. We are now more steadfast in our belief that Novan remains a compelling investment opportunity. Our highlights can be summarized and easily remembered on one hand. We're gonna count down. five, product candidates in our development pipeline, all nitric oxide-based formulations. four, products promoted by our commercial team. three, near-term value creators. two, priority products and one, Lead product candidate. two, business units. We have an R&D engine and a commercial platform. Finally, one, NDA submission targeted before the end of 2022. We've created a medical dermatology company that has the capabilities to discover, research, and develop innovative therapies and bring medications to patients with diseases of the skin. Our NITRICIL technology has generated multiple nitric oxide-based formulations to address multiple medical conditions with unmet needs. We've recently completed the upfitting and launch of our small-scale manufacturing facility in Durham, North Carolina, for our drug substance. We're able to tout an experienced dermatology commercial platform from supply to engagement to sales effectiveness. We've established healthcare relationships as well as product launch experience. We are now positioned to detail SB206 or KINSOLUS, if approved. Integration, let me talk a little bit about that. We're 65 days post-closing of the EPI acquisition. 20 days for accounting purposes, which John will speak to shortly. The transition has been smooth and generally on schedule and as planned. We've aligned our teams, focusing on one culture, one set of IT systems and processes, and leveraging our synergies. I'm truly pleased with our progress to date. The seamless integration enables us to focus on the execution of our growth strategy for Novan. We'll now take a few minutes for John A. Donofrio to review Novan's commercial platform, including our promoted products. As you heard, John is Novan's COO and President of EPI Health, a Novan company. John, over to you. Thank you, Paula, and good morning, everybody. Paula mentioned we are now a fully integrated medical dermatology company with a strong leadership team, proven execution with both an R&D engine and now a commercial platform. I'm gonna spend some time this morning to discuss three key areas. First, our commercial capabilities. Second, I'd like to provide background on our promoted product portfolio and therapeutic areas that serve our patients and close with an update on our Q1 prescription performance. Paula mentioned the rationale and benefit of acquiring EPI Health along with our product portfolio was our commercial platform. We have an established commercial presence across the medical dermatology community with the ability to reach over 7,000 healthcare practitioners. When you think of our commercial platform, we start with supply chain management of our third-party suppliers, along with an optimized demand management process. We have built our distribution capabilities to both wholesalers and direct network pharmacies. We enhanced our managed care capabilities with the payers and patient affordability programs to ensure patients have affordable access to all our medications. Our sales organization consists of four regions and 42 territories and has more than doubled over the past three years. We've also upgraded our sales training and our field sales support organizations. Our team has either launched or relaunched four products in the last four years, and we believe that experience will provide a solid foundation for our potential future launches. We have a brand marketing team focused on the product and disease state messaging and education throughout our portfolio. Lastly, we built strong professional relations engagement with our healthcare practitioners and key opinion leaders across the country. When we look at our commercial capabilities, what differentiates us is our dedicated employees and our focus on execution, data, and performance. We have complemented our commercial capabilities with strong financial management, analytics, and a reporting platform that focuses on clear alignment of our financial and operational data and metrics. When we step back, we look at this as one platform that is aligned on a common set of objectives. We are also in the process of integrating the legacy Novan commercial organization into our platform to make us even stronger as we prepare our company for potential future launches. Our commercial platform is focused on field readiness, high engagement with our customers and employees, along with a strong performance management across our organization to ensure we deliver value to our shareholders and the patients that we serve. There are multiple channels in dermatology space, medical prescription, device, aesthetics, procedures, OTC. Here at Novan, we are solely focused on providing a portfolio of prescription dermatology products across multiple disease states, and not just one product and not just one disease state. Over the past four years, we specifically focused our efforts on unmet needs in four key disease states in medical dermatology. We compete and provide our patients innovative solutions in psoriasis, rosacea, acne, and atopic dermatitis. We have a demonstrated commitment to the medical dermatology community, not only with our current promoted products, but with our strong development pipeline. When thinking about our pipeline, our commercial platform is built to expand disease states within medical dermatology and to call on other specialties, like pediatrics. I would like to now provide an overview of our diverse promoted product portfolio. In psoriasis, we launched Wynzora cream last summer for the treatment of plaque psoriasis. This is a combination of calcipotriene and betamethasone dipropionate and works on both flares and maintenance of the disease. Wynzora delivers on three key attributes to the patient, efficacy, safety, and adherence in a novel cream formulation using an innovative pad technology. For rosacea, Rhofade is a topical prescription medication indicated for the treatment of persistent facial erythema, PFE, or specifically redness. The majority of rosacea products address the inflammation of rosacea, and there was an unmet need in addressing the redness, and Rhofade has become a market leader in the PFE category. For acne, Minolira is an oral antibiotic treatment with the active ingredient of minocycline. Minolira provides our patients with innovative technology approach to ensure consistent delivery of the active ingredient, limiting variability and potential side effects to our patients. Lastly, Cloderm. Cloderm is a known steroid with a 40-year trusted history with healthcare practitioners for patients with dermatoses. As mentioned, our products are promoted over 7,000 healthcare practitioners across the country by our existing sales force of 42 territories. Now let's talk performance. We shared with you the fundamentals of our commercial platform, the disease states we serve our patients, and our diverse product portfolio. Now let's discuss how our team performed in the first quarter of 2022. I am pleased to report significant growth in three of our four promoted products. Beginning with Cloderm, prescriptions were slightly down over the last year and flat over previous quarter, in line with expectations of adding a fourth product within our sales team call cycle when we launched Wynzora. Speaking of Wynzora, which was launched in mid-2021, has shown consistent growth month-over-month and quarter-over-quarter since launch. For Rhofade, we're excited to have closed the quarter with the strongest quarter in the history of the brand, with over 37,000 prescriptions, nearly 50% above last prior year and 14% over its previous all-time high quarter. Team did a fantastic job. Speaking of fantastic job, Minolira also had strong growth quarter with almost 50% above Q1 2021 and 14% over previous quarter. In summary, we're extremely pleased with this performance in a quarter that historically is lower or flat to Q4 due to end-of-year seasonality and feel this demonstrates our commercial platform's ability to execute and deliver going forward. Paula, I'll now hand it back over to you and John, and thank you very much. All right. Super. Thanks, John. You know, I think your next question may be, well, what are you doing to keep this going or make it even better? Well, our commercial organization will be focused on seven key growth drivers to expand our promoted products. Continued expansion of our sales force size and structure, starting with a national sales leader starting this week, and planned expansion of our 42 territories in the second half of this year. Both the companies, Novan and EPI Health, have established good coverage at industry conferences and meetings, but now as a combined company, we plan to expand that presence at the national, regional, and even local levels. We'll continue the momentum of our promoted products with a heightened level of focus with our key opinion leaders in our current disease states, as well as our potential future disease states, along with the continued sales force execution and promotional marketing programs that continue to drive growth across the portfolio. Lastly, we have an excellent opportunity to add potential value to our shareholders by perhaps licensing Rhofade outside the U.S. It's been an exciting time for our commercial organization with the announcement of our combined R&D and commercial company, strong integration of our culture, and our strong quarter one prescription growth across the portfolio. From a commercial perspective, we have our key areas of focus, and we're extremely excited as we look to our future. I'll now spend some time on our development pipeline, our R&D engine. It provides a near-term opportunity to leverage our platform technology to fuel our pipeline and ultimately provide new commercial opportunities. Each product candidate has its own compelling addressable market, globally and domestically, with Novan's pending solutions meeting different current medical needs for diseases of the skin and others. Just quickly for those new to the Novan story, our NITRICIL technology enables us to create NCEs that store large amounts of nitric oxide gas in a stable, solid form. The advantage of our technology includes tunability, stability, high storage capacity, and targeted delivery. We believe that our ability to deploy nitric oxide in a solid form on demand and in localized formulations allow us the potential to improve patient outcomes in a variety of diseases. You can see here we've treated nearly 4,000 patients with the active ingredient, berdazimer sodium. We've seen a compelling safety profile in the clinic across the platform thus far, and we have a solid patent protection with formulation and indication-specific IP out to 2035. Our lead product candidate is SB206, which is berdazimer gel 10.3%. It's a potential topical prescription treatment for molluscum contagiosum. In 2021, we reported what I've referred to as robustly positive efficacy results from our pivotal phase III study. Molluscum is a highly contagious condition prevalent primarily in children aged one to 14, for which there's no FDA-approved prescription treatment. Dermatologists and pediatricians remain concerned with the tolerability of the currently sought office-based procedures. Our pivotal phase III study, known as B-SIMPLE4, demonstrated clinical and statistical evidence of efficacy with our primary and secondary endpoints. You may ask, "What's next?" Well, we are now preparing our NDA submission. As normal course of business, we've had our pre-NDA meetings with the agency in March and then received written minutes from the agency in April. This confirms what we need to complete before submitting our NDA package, and part of that is completing customary stability testing of GMP batches of our drug substance and drug product. Importantly, we remain on track to meet our targeted submission date before the end of the year. We've been planning toward the potential launch of SB206, or KINSOLUS, if approved, for some time now. We identified the best and most compelling path that delivers value, and that was to acquire an established business, EPI Health. That commercial platform will promote SB206, if approved. In the meantime, we have key activities ongoing to prepare for a potential launch. These include our commercial scale manufacturing capability, which is up and running, a pricing and reimbursement strategy, which is in progress, outreach to KOLs through our medical team, which is ongoing, and sales force preparedness, which is really to come. At Novan, as you know, we've said it many times before, we plan for success, and a product launch is no different. Novan also has a full technology platform poised to fuel potential future growth for the company. In addition to our lead product candidate, we have two other priority product candidates, SB204 for acne vulgaris and SB019 for infectious diseases, specifically SARS-CoV-2. The progression of both programs is dependent upon additional funding. Our next milestone for SB204 is to initiate one final phase III study. For SB0 19, we are awaiting FDA feedback on our pre-IND submission before commencing down the phase I path. Based on a series of in vitro and in vivo assessments in 2020 and 2021 with berdazimer sodium, we then submitted our pre-IND in April of this year. In addition to our priority dermatology platform, we have several other product candidates in the wings with potential future value. All product candidates provide Novan the opportunity to collaborate in the U.S. and potentially outside the U.S. To report on our first quarter results now, I'll turn the call over to John M. Gay. Thank you, Paula, and good morning. Due to the timing of the acquisition of EPI Health on March 11, we only had 20 days of commercial activity reflected in our three months ended 3/31 financials. However, based on the trends of script activity for the complete first quarter, which John touched on earlier, we are bullish on the future of our promoted product portfolio. Before I touch on some of the key data points for this quarter, I would like to let our participants know that while we are excited for the path set before us, we are still in the process of fully integrating our new company, our personnel, and our operations. As such, we are not yet in a position to provide guidance as it relates to 2022 revenues or EBITDA. However, as John noted, we certainly see opportunities for growth in our promoted product portfolio. For the first quarter ended March 31, 2022, our commercial operations segment reported total revenue of $1.2 million. Again, this represents only 20 days of consolidated activity for this business segment, which represents the legacy EPI Health business. Our commercial operations segment included net product revenues from sales of our commercial portfolio of $0.7 million, driven primarily by Rhofade, which was $0.8 million for the 20 days ended March 31st. Net revenues from the sale of Minolira and Cloderm total $0.1 million for the 20 days ended March 31. In addition to these positive trends for our products, we did have a reduction in revenue of approximately $0.2 million for certain adjustments, including those products not currently promoted and also related to certain accruals that were assumed as of the acquisition date. In addition, our commercial operations segment also generated $0.5 million of license and collaboration revenues, primarily related to our agreement with MC2 Therapeutics for Wynzora, totaling $0.4 million. This amount includes not only the commercialization fee we receive as part of that arrangement, but also the reimbursement of certain covered expenses. Our research and development operations segment, which is comprised of the legacy Novan business, reported total revenue of $0.7 million for the three months ended March 31, 2022. For the three months ended March 31, 2021, our R&D operations segment generated $0.8 million of revenue. Our license and collaboration agreement with Sato Pharmaceutical comprised the majority of this revenue. In addition, during the first quarter of 2022, we received a time-based milestone payment of $4.3 million related to this agreement. Now turning to our operating expenses. Our research and development operations segment incurred R&D expenses of $4.8 million for the three months ended March 31st, 2022, compared to $6.4 million for the three months ended March 31st, 2021. The decrease is primarily related to the SB206 program based on the timing of the B-SIMPLE4 trial. SG&A expenses were $10 million for the three months ended March 31, 2022, compared to $2.7 million for the three months ended March 31, 2021. This increase of approximately $7.3 million was primarily due to $4 million of non-recurring transaction-related expenditures incurred in connection with the EPI Health acquisition, $1.6 million of expenses incurred to support the conduct of EPI Health's commercial sales operations during the quarter, $0.8 million increase in support costs related to the SB206 pre-launch strategy and commercial preparation, and finally, $0.9 million increase in other G&A costs. The total net loss on a consolidated basis was $13.4 million for the first quarter of 2022 as compared to $9 million for 2021. As of March 31, 2022, we had a total cash balance of $35.5 million. We believe that our existing cash balance plus expected receipts associated with product sales from our commercial portfolio will provide us with adequate liquidity to fund our planned operating needs into the early fourth quarter of 2022. I will refer you to our Form 10-Q filed this morning for additional detail regarding management's projections and planned operating, development, and commercial activities for the remainder of the year. With that, I will turn it back to Paula. Great. Thanks, John. I'm just, you know, back on that 56% growth in promoted products of, you know, prescriptions from the first quarter of 2021. It's quite the growth, as John Donofrio mentioned earlier as well. We are pleased with Novan's foundational leap forward in quarter one. If the strength of scripts in the first quarter is any indication, we have a commercial organization poised for growth. We continue to advance our efforts toward an NDA submission in 2022, having received FDA feedback and marching forward with our to-do list. We are planning for success and preparing ourselves for potential product launch of KINSOLUS, if approved. We continue to pursue, evaluate, and consider collaborations that could expand our existing commercial products. We continue to explore our proprietary development pipeline for future growth opportunities. In closing, even with the challenges that we all see in the stock markets, the interest rate environment, and the geopolitical landscape, we at Novan remain energetic, focused, and excited for the future based on our integration activities this quarter and the evolution of our company with the addition of EPI Health. Thank you. Operator, I'd like to turn the call back to you to facilitate our Q&A session. Ladies and gentlemen, if you have a question or comment at this time, please press star then one on your telephone keypad. If your question has been answered or you wish to remove yourself from the queue, simply press the pound key. Again, if you have a question or comment at this time, please press star then one on your telephone keypad. Our first question or comment comes from the line of Jennifer Kim from Cantor Fitzgerald. Your line is open. Thanks for taking my questions. I have two to start off. Maybe I know that you're not providing guidance yet, but do you believe that the EPI Health business is positioned to grow year-over-year on a full year basis? I think in the 2021 operating revenues is around $17.6 million. And you know, in the first quarter is only 20 operating days. But on a full year basis, do you believe it can grow off that? And then my second question is, I think previously you said that you expect to increase the number of U.S. territories covered from 42 to 50 this year. I'm wondering, is that still the plan? And what is the general timing on that through the course of the year? Thanks. Thank you, Jennifer. Appreciate your questions. I'm gonna ask John Gay to take the first one on the growth, and then I'll ask John Donofrio to provide you the update on our plan regarding the reps. Thanks, Paula. Good morning, Jennifer. Thanks for your question. With respect to the first part of that, you know, do we expect, you know, year-over-year growth? I would yes, based upon what John Donofrio was able to articulate earlier in the prepared remarks. I will say this, though, and kind of to the point of my comments, on a full year basis, which is the metrics that we'll use to compare, keep in mind that we'll only have consolidated results, you know, March 11th going forward. Just keep that in mind. On a totality basis as it relates to the operations of the legacy EPI Health business, yes, we see year-over-year growth. Thanks. John Donofrio? Yes. In regards to sales force expansion, yes, we are still planning on expanding from 42 territories to 50. We plan that to start that in Q3 of 2022. When you think about it just quickly, you know, we'll be going from four to seven regions. We'll be reorganizing the regions, and then it'll take time to bring in the managers and then the respective representatives accordingly. We expect to be complete in early Q4, as it usually is about a two to three month process. Okay, great. That's helpful. Maybe, one more question here. I think I saw that your cash runway extended a bit into the fourth quarter, and I'm wondering what were the main drivers of being able to extend that? Yeah, sure, Jennifer. With respect to that, obviously, with the acquisition and the strong performance of Rhofade in Q1, with respect to the level of sales, that increased kind of our cash collection as it relates to that activity. That's certainly part of the equation as it relates to extending the runway into Q4. Okay, great. Thanks, everyone. Thanks, Jennifer. Thank you. Operator, next. Thank you. Our next question or comment comes from the line of Kemp Dolliver from Brookline Capital Markets. Your line is open. Great. Thanks, good morning. Just quickly, you know, the accounts receivable on the books are roughly $20 million, which is a pretty large number for a business of this size. You know, it does appear from the Q that, you know, there's some offsetting payables. John, could you just walk through how that number's going to show up on the income statement going forward? Certainly Kemp. Good morning. You know. I mean, on the balance sheet. Sorry. On the balance sheet. Yeah, certainly. As it relates to the acquisition, what came over is the from the acquisition date was roughly $20 million of receivables, and obviously we've collected down on that to get to the 3/31 balance. You know, a couple of key drivers that we saw from a cash perspective was the collection of those AR balances, again, driven by the Rhofade activity during the first quarter. Also, again, I touched on the Sato payment. That was kind of the flux, if you will, from a balance sheet perspective of the AR. I think your question to you know, what's it gonna look like going forward? I mean, obviously, it's gonna be highly dependent upon the level of sales. You know, keep in mind that those accounts receivable are directly related to the gross, you know, amounts that the company gets in as part of the gross to net adjustments, you know, the amount that we get versus what there's an offsetting liability that we'll have to pay against in the future. Okay. That makes a lot of sense. Second question relates to the Wynzora revenue. Is what you're booking essentially strictly for end-period revenue on an ongoing basis? Yes. For that, the revenue is two pieces, the commercialization fee that we get as part of that, but also the reimbursement of certain expenses. With our distribution agreement and commercialization agreement with MC2, they cover certain expenses. The revenue is comprised of two pieces, the fee and also the recoupment of those expenses that are funded. Okay. And then, finally, with regard to the sales force reorganization coming ahead, and again, you're not giving guidance, but when I hear sales force reorganization, I think that they're usually short-term bumps associated with those. Is that something we should take into consideration when we look at the second half of the year? John Donofrio, do you wanna address that? Because I would say it. Yeah. Anyway, I'll let John comment. Yeah. Yeah, I'll be glad to. Thanks, and great question. We look at it more as an expansion than a reorganization. I think your point is spot on in historical reorganizations where you change a lot of stuff. This has kinda been in the plans for over a year. Territories have already been targeted of where we'll go. The fact that we're doing it over, you know, a three-month kind of period, we feel strong that our implementation and our strict targeting will keep the momentum going forward, as we continue to move forward. Do not see it to be a hindrance, but more of an opportunity going forward. Great. Thanks. I'm done. All right. Thanks, Kemp. Operator? Thank you. Our next question or comment comes from the line of John Vandermosten from Zacks. Your line is open. Good morning. Just one for me on the cash flow statement. It looked like you had positive cash from operations, but net loss was $13 million. Can you explain just the difference there and if that will reverse in the second quarter? Sure. Thanks, John. Good morning. Keep in mind, the cash flow statement is a little bit complex this quarter because of the acquired balances and the way that it flows through, you know, our consolidated Q1 cash flow statement. Yeah, you're correct. As it relates to the activity for the acquisition balances and what we had for the 20-day sub-period, as we've been calling it, we did have, you know, provided cash about $0.8 million. You know, again, that will be subject, you know, to continued activity on the P&L, and, you know, we can expect for that to change based upon our net loss and the amount of sales that we are able to execute upon. Okay. Thanks, John. Can you update us on the number of employees you have right now after the acquisition? After the acquisition, it's roughly 100. That includes all the EPI Health folks and the legacy Novan. On a consolidated basis, it's roughly 100. Great. Thank you, guys. Thank you. Our next question or comment comes from the line of Jonathan Aschoff from Roth Capital Partners. Your line is open. Thanks. Good morning. I was wondering, can you guys help us understand your best competitive edge against, you know, I guess, similarly sized dermatological companies, you know, even if you just kinda restrict that answer to Wynzora and Rhofade? Yeah, I think, thank you. Thank you, Jonathan. I think John Donofrio could probably answer that best. Yeah. Good morning, Jon. How are you? Fine. You? Great. Thank you very much. I think from a competition perspective, we look at, first of all, you know, we have a full product portfolio across four disease states. We look at it, we sell as an EPI Health company. When you look at Rhofade, specifically, we see, you know, basically the acceptance of treating persistent erythema differentiates us significantly. We only have one competitor in that space and have over 90% of the market share in PFD for redness. We have exciting new data that's come out on the medical front that shows using Rhofade once a day, every day, makes a significant difference in the patient's treatment regimen. We're excited about that. We also feel comfortable, you know, in the launch of Wynzora. You know, we've taken about 20% of the share of the combination, topical market, with the goal of, you know, continuing to expand that market and taking share, and also addressing the larger steroid, single steroid market and the ability to expand, Wynzora is a real advantage over potent steroids. We feel like in those two categories. We'll use that just through the seven, you know, kind of capabilities that Paula went through. When we think about our field execution and expansion, we've demonstrated that now. We also feel like the data that we have and the information, the medical education and promotion of these products, including sampling, will help us as we continue to grow and go forward. As we've mentioned, just our robust presence at conferences, medical education awareness, and also just our professional relations and key opinion leadership relationships have only expanded over the last few years, and we figure as a combined company will be even better. All those areas combined, it's just not one, we feel like positioned as well against the competition going forward. Thank you very much for that answer. You know, back on April 26th when you had a presentation, you know, you were talking about companies interested in you for one reason or another. What is the balance of, you know, interested sellers and interested buyers, currently, you know, talking to you guys? Is everyone trying to sell you something? Does everybody wanna buy the new Novan? What's kind of the balance there? Thanks, Jonathan, for being on and for that question. I would say that, you know, to be frank, the most interest is a lot of people wanting us to buy things. You know, partner with them, interested like the platform and what we're doing, and so there is some interest there. You know, we'll continue, as I said, to evaluate opportunities and, you know, with the focus on ourselves getting hopefully SB206 approved and making sure that's a priority for us. Thanks for that. Just sort of a little follow-up to that. Are any of them who wish to sell you a product wishing to sell you themselves and maybe that comes with some cash as well? Or is it really just, you know, buy this product? Yeah. I really can't share any detail on that, you know, Jonathan. It's, you know, too early to even, you know, to summarize any of that interest. Appreciate the question, but I don't think I can answer it. Okay. Lastly, and maybe you've mentioned this many times, can you remind us of what stops somebody with severe acne using an approved KINSOLUS, given that both are, you know, 10.3% topical formulations? Yeah. They are the same API, which is berdazimer sodium, but there's a different volume, and there's a different proton donor source. It's a dual administration, and they are very different. Molluscum, SB206, is a spot treatment, so it's just being applied to each lesion. For acne it would be a field treatment, so put on the whole face. They're two very different formulations and amounts of NO being applied, so they should not be used one for the other. Yeah, that sounds prohibitive enough. Thank you, guys. Yeah. Thanks for that. Operator, I got a text. We have another analyst trying to get onto the call, so I don't know if there's another one waiting. I'm showing no additional questions in the queue at this time, ma'am. Okay. Well, we will speak to them offline then. Thank you, all. Let me just summarize if there are no other questions, operator, right? There are no other? That's correct, ma'am. All right. Let me just summarize. Quarter one, it's been a foundational leap forward for Novan, and we thank our shareholders. The acquisition of EPI Health has propelled us into that fully integrated dermatology company. Not only do we have our proprietary NITRICIL technology, which we know has the potential of generating NCEs, we have a first-class sales team and a supporting commercial infrastructure to propel us forward. With two key products in the bag, with Rhofade and Wynzora, and a watchful eye toward a potential approval and launch of SB206, it is a very exciting time for Novan. It's a countdown. 5, 4, 3, 2, 1, and we're ready to go. Thank you all for attending this morning, and have a great week. Ladies and gentlemen, thank you for participating in today's conference. This concludes the program. You may now disconnect. Everyone, have a wonderful day.